Are the newer antidepressant drugs as effective as established physical treatments? Results from an Australasian clinical panel review

Australian and New Zealand Journal of Psychiatry

Volumn 33, Issue 6, 1999, Pages 874-881

  Parker, Gordon ^a   Mitchell, Philip ^a   Wilhelm, Kay ^a   Menkes, David ^b   Snowdon, John ^c   Schweitzer, Isaac ^d   Grounds, David ^e   Skerritt, Paul ^f   Roy, Kay ^a   Hadzi Pavlovic, Dusan ^g  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b DUNEDIN HOSPITAL   (New Zealand)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e The Anxiety Clinic   (Australia)

^f Mental Health   (Australia)

^g NONE

Author keywords

Antidepressant treatments; Depression; Drug efficacy

Indexed keywords

MIANSERIN; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ARTICLE; AUSTRALIA; DEPRESSION; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANCHOLIA; NEW ZEALAND; SELF REPORT;

EID: 17044451981     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1614.1999.00648.x     Document Type: Article

References (26)

1. Wells KB. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. American Journal of Psychiatry 1999; 156:5-10.
2. Healy D. The Antidepressant Era. Cambridge: Harvard University Press, 1997.
3. Janicak PG, Davis JM, Preskorn SH, Ayd FJ. Principles and practice of psychopharmacotherapy. Management of an acute depressive episode. Baltimore, MD: Williams & Wilkins, 1993:226-246.
4. Agency for Health Care Policy and Research. Treatment of depression-newer pharmacotherapies. Summary. Evidence Report No. 7. San Antonio, TX: Report from University of Texas Health Science Center, 1999.
5. Schatzberg A. Antidepressant effectiveness in severe depression and melancholia. Journal of Clinical Psychiatry 1999; 60 (Suppl.4):14-21.
6. The Quality Assurance Project. A treatment outline for depressive disorders. Australian and New Zealand Journal of Psychiatry 1983; 17:129-146.
7. Overall JE, Hollister LE, Porkorny AD, Casey JR, Katz G. Drug therapy in depressions. Controlled evaluation of imipramine, isocarboxazid, dextroamphetamine-amobarbital and placebo. Clinical Pharmacology and Therapeutics 1962; 3:16-22.
8. Medical Research Council. Clinical trial of the treatment of depressive illness. British Medical Journal 1965; 1:831-836.
9. Lader M, Herrington R. Biological Treatments in Psychiatry. 2nd ed. Oxford: Oxford University Press, 1996.
10. Danish University Antidepressant Group. Citalopram. Clinical effect profile and comparison with Clomipramine: a controlled multicenter study. Psychopharmacology (Berlin) 1986; 90:131-138.
11. Danish University Antidepressant Group. Paroxetine. A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than Clomipramine in a controlled multicenter study. Journal of Affective Disorders 1990; 18:289-299.
12. Danish University Antidepressant Group. Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorders 1993; 28:105-116.
13. Roose SP, Glassman AH, Attia E, Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. American Journal of Psychiatry 1994; 151:1735-1739.
14. Peselow ED, Sanfilip MP, Difiglia Q, Fieve RR. Melancholic/endogenous depression and response to somatic treatment and placebo. American Journal of Psychiatry 1992; 149:1324-1334.
15. Nelson JC, Mazure CM, Jadow PI. Characteristics of desipramine-refractory depression. Journal of Clinical Psychiatry 1994; 55:12-19.
16. Fava M, Uebelacker LA, Alpert JE, Nierenberg A, Pava JA, Rosenbaum JF. Major depressive sub-types and treatment response. Biological Psychiatry 1997; 42:568-576.
17. Parker G, Hadzi-Pavlovic D. Melancholia. A disorder of movement and mood. New York: Cambridge University Press, 1996.
18. American Psychiatric Association. Treatment of Psychiatric Disorders, 3. Washington: American Psychiatric Association, 189.
19. Crismon ML, Trivedie M, Pigott TA et al. The Texas Medication Algorithm Project: report of the Texas consensus conference panel on medication treatment of major depressive disorder. Journal of Clinical Psychiatry 1999; 60:142-156.
20. Hylan TR, Kotsanos JG, Anderson JS et al. Comparison of a decision analytic model with results from a naturalistic economic clinical trial: an application to evaluating alternative antidepressants. American Journal of Managed Care 1996; 2:1211-1223.
21. Rosenbaum JF, Hylan TR. Costs of depressive Disorders. In: Maj M, eds. Evidence and practice in psychiatry: depressive disorders. Geneva: World Psychiatric Association (in press).
22. Parker G, Roy K, Hadzi-Pavlovic D et al. Sub-typing depression by clinical features: the Australasian data base. Acta Psychiatrica Scandinavica (in press).
23. Abrams R. Electroconvulsive therapy. 3rd ed. New York: Oxford University Press, 1997.
24. Task Force on Electroconvulsive Therapy. The practice of electroconvulsive therapy: recommendations for treatment, training and privileging. Washington, DC: American Psychiatric Association, 1999.
25. Boyce P, Judd F. The place for the tricyclic antidepressants in the treatment of depression. Australian and New Zealand Journal of Psychiatry 1999; 33:323-327.
26. Beerworth EE, Tiller JWG. Liability in prescribing choice: the example of the antidepressants. Australian and New Zealand Journal of Psychiatry 1998; 32:560-566.